Journal Logo

Simultaneous Sessions I: Novel agents and therapies for CLL

S107 FIVE-YEAR FOLLOW-UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

Tedeschi, A.1; Burger, J.2; Barr, P.M.3; Robak, T.4; Owen, C.5; Ghia, P.6; Bairey, O.7; Hillmen, P.8; Coutre, S.9; Devereux, S.10; Grosicki, S.11; McCarthy, H.12; Li, J.13; Simpson, D.14; Offner, F.15; Moreno, C.16; Dai, S.17; Lal, I.17; Dean, J.P.17; Kipps, T.J.18

Author Information
doi: 10.1097/01.HS9.0000558648.00957.de
  • Free

Abstract

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.